iSpecimen Inc. filed a Form 8-K on November 2, 2026, reporting the final voting results from the reconvened special meeting of stockholders held on October 30, 2026, at which shareholders approved a proposal to effect a reverse stock split of the company's common stock.

Key Highlights

  • Proposal approved: Stockholders voted to approve an amendment to the Fifth Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 1:10 to 1:100, with the exact ratio to be determined by the Board of Directors.
  • Vote tally: 1,152,016 shares voted FOR, 142,944 voted AGAINST, and 868 abstained; there were no broker non-votes.
  • Quorum: A total of 1,295,828 shares were present in person or by proxy, constituting approximately 51.5% of shares outstanding and entitled to vote.
  • Record date shares: As of August 12, 2026, there were 2,518,590 shares of common stock outstanding and entitled to vote.
  • Meeting context: The October 30, 2026 meeting was a reconvening of a special meeting originally convened on October 9, 2026, at which Proposal No. 2 had been adjourned.

iSpecimen Stockholders Vote on Reverse Stock Split Ratio at Adjourned Special Meeting

According to the filing, iSpecimen Inc. (NASDAQ:ISPC) originally convened a special meeting of stockholders on October 9, 2026, at which Proposal Nos. 1, 3, 4, and 5 were voted upon and Proposal No. 2 was adjourned. The company reconvened the special meeting on October 30, 2026 solely to address Proposal No. 2, which concerned a potential reverse stock split of the company's outstanding shares of common stock.

The filing states that Proposal No. 2 sought approval of an amendment to the company's Fifth Amended and Restated Certificate of Incorporation to permit a reverse stock split at a ratio in a range of one-for-ten (1:10) to one-for-one hundred (1:100), with the Board of Directors retaining discretion to set the exact ratio. As disclosed, the proposal was governed by Section 242(d)(2) of the Delaware General Corporation Law, which required that votes cast "FOR" the proposal exceed votes cast "AGAINST" the proposal, with abstentions having no effect on the outcome.

The filing reports that 1,152,016 shares were cast in favor and 142,944 shares were cast against, with 868 abstentions and zero broker non-votes. The proposal was approved. The filing was signed by Shahin Behroyan, Chief Executive Officer of iSpecimen Inc., and dated November 2, 2026. No other business was reported as having been brought before the adjourned meeting.

What Was Disclosed

iSpecimen Inc. disclosed the final voting results from its October 30, 2026 adjourned special stockholder meeting, at which Proposal No. 2 - approval of a reverse stock split at a ratio between 1:10 and 1:100 - received 1,152,016 votes in favor and was approved.